BG103393A - Метод за получаване на заместени пиридини - Google Patents

Метод за получаване на заместени пиридини

Info

Publication number
BG103393A
BG103393A BG103393A BG10339399A BG103393A BG 103393 A BG103393 A BG 103393A BG 103393 A BG103393 A BG 103393A BG 10339399 A BG10339399 A BG 10339399A BG 103393 A BG103393 A BG 103393A
Authority
BG
Bulgaria
Prior art keywords
preparation
formula
substituted pyridines
compounds
aminogroup
Prior art date
Application number
BG103393A
Other languages
English (en)
Inventor
Keith DEVRIES
Robert DOW
Stephn WRIGHT
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG103393A publication Critical patent/BG103393A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретението се отнася до методи за получаване на съединения с формула@@които са антагонисти на бета-адренергични рецептори, и до методи за получаване на определени междинни съединения с формула@@вкоято R1 е нитро, амино или защитена аминогрупа,R2 е Н, флуоро, хлоро, CF3, нитро, (C1-C4)алкил, (C1-C4)алкокси, амино или защитена аминогрупа и X1е ОН или подходяща отцепваща се група, използвана в този метод. Изобретението се отнася и до нови съединения с формула II.
BG103393A 1996-11-14 1999-05-11 Метод за получаване на заместени пиридини BG103393A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3088096P 1996-11-14 1996-11-14
PCT/IB1997/001367 WO1998021184A1 (en) 1996-11-14 1997-11-03 Process for substituted pyridines

Publications (1)

Publication Number Publication Date
BG103393A true BG103393A (bg) 2000-07-31

Family

ID=21856496

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103393A BG103393A (bg) 1996-11-14 1999-05-11 Метод за получаване на заместени пиридини

Country Status (32)

Country Link
US (1) US6291489B1 (bg)
EP (1) EP0938476B1 (bg)
JP (1) JP3510635B2 (bg)
KR (1) KR20000053314A (bg)
CN (1) CN1237160A (bg)
AP (1) AP805A (bg)
AR (1) AR010584A1 (bg)
AT (1) ATE319687T1 (bg)
AU (1) AU4634697A (bg)
BG (1) BG103393A (bg)
BR (1) BR9712951A (bg)
CA (1) CA2270386C (bg)
CO (1) CO4930261A1 (bg)
DE (1) DE69735433D1 (bg)
EA (1) EA199900375A1 (bg)
GT (1) GT199700118A (bg)
HR (1) HRP970612A2 (bg)
ID (1) ID18898A (bg)
IL (1) IL129688A0 (bg)
IS (1) IS5029A (bg)
MA (1) MA24401A1 (bg)
MY (1) MY132507A (bg)
NO (1) NO992296D0 (bg)
OA (1) OA11044A (bg)
PA (1) PA8441401A1 (bg)
PE (1) PE10299A1 (bg)
TN (1) TNSN97172A1 (bg)
TR (1) TR199901063T2 (bg)
UY (1) UY24774A1 (bg)
WO (1) WO1998021184A1 (bg)
YU (1) YU22099A (bg)
ZA (1) ZA9710186B (bg)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9909555A (pt) * 1998-04-08 2000-12-19 Novartis Ag Novartis S A Novar Herbicidas
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
KR20010102198A (ko) * 1999-02-16 2001-11-15 후루타 타케시 치환 아세틸피리딘 유도체 및 그를 이용하는 광학활성 β3작용제 중간체의 제조 방법
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
EP1078924B1 (en) * 1999-07-23 2004-10-20 Pfizer Products Inc. Intermediates and a process for producing beta-adrenergic receptor agonists
JPWO2003033468A1 (ja) * 2001-10-17 2005-02-03 株式会社カネカ （Ｓ）−α−ハロメチルピリジンメタノール誘導体の製造方法
MXPA04008298A (es) 2002-02-27 2004-11-26 Pfizer Prod Inc Procesos e intermedios utiles en la preparacion de agonistas de receptor beta-3 adrenergico.
AU2003209527A1 (en) * 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
KR100751163B1 (ko) 2003-05-09 2007-08-22 에프. 호프만-라 로슈 아게 알파-1 아드레날린 작용물질로서의 메틸 인돌 및 메틸피롤로피리딘
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US20110160249A1 (en) 2008-05-23 2011-06-30 Schaab Kevin Murray 5-lipoxygenase-activating protein inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
US5019578A (en) 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
BR9406823A (pt) 1993-06-14 1996-03-26 Pfizer Aminas secundárias e agentes anti-diabéticos e antiobesidade
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
EP0828712A1 (en) 1995-05-10 1998-03-18 Pfizer Inc. Beta-adrenergic agonists
JPH11504649A (ja) * 1995-05-10 1999-04-27 ファイザー・インコーポレーテッド β−アドレナリン作働性アゴニスト

Also Published As

Publication number Publication date
US6291489B1 (en) 2001-09-18
CA2270386A1 (en) 1998-05-22
CA2270386C (en) 2004-08-03
TNSN97172A1 (fr) 2005-03-15
AU4634697A (en) 1998-06-03
ID18898A (id) 1998-05-20
HRP970612A2 (en) 1998-08-31
CO4930261A1 (es) 2000-06-27
UY24774A1 (es) 1998-05-05
EP0938476A1 (en) 1999-09-01
YU22099A (sh) 2001-09-28
AP9701147A0 (en) 1998-01-31
JP3510635B2 (ja) 2004-03-29
TR199901063T2 (xx) 1999-08-23
CN1237160A (zh) 1999-12-01
BR9712951A (pt) 1999-12-07
ZA9710186B (en) 1999-05-12
MY132507A (en) 2007-10-31
PA8441401A1 (es) 2000-05-24
KR20000053314A (ko) 2000-08-25
NO992296L (no) 1999-05-12
PE10299A1 (es) 1999-02-10
ATE319687T1 (de) 2006-03-15
AR010584A1 (es) 2000-06-28
NO992296D0 (no) 1999-05-12
IS5029A (is) 1999-04-16
OA11044A (en) 2002-02-20
MA24401A1 (fr) 1998-07-01
AP805A (en) 2000-01-28
EP0938476B1 (en) 2006-03-08
DE69735433D1 (de) 2006-05-04
IL129688A0 (en) 2000-02-29
JP2000504347A (ja) 2000-04-11
WO1998021184A1 (en) 1998-05-22
GT199700118A (es) 1999-05-05
EA199900375A1 (ru) 1999-12-29

Similar Documents

Publication Publication Date Title
BG103393A (bg) Метод за получаване на заместени пиридини
YU5399A (sh) Supstituisani pirido-ili pirimido-derivati koji sadrže 6,6- ili 6,7-biciklične prstenove
DK0641328T3 (da) Broforbundne, azabicykliske derivater som substans P-antagonister
EA200100914A1 (ru) Цементирующие составы и способы применения таких составов для цементирования нефтяных скважин или подобных сооружений
SG64399A1 (en) Process for preparing compositions useful as intermediates for preparing lubricanting oil and fuel additives
PL329681A1 (en) Halogen-substituted inhibitor of proteinous kinase c
SV2002000244A (es) Metodos y compuestos para inhibir mrp1 ref.x-13353
DK0815065T3 (da) Isoleringsmørtel
ES2182349T3 (es) Procedimiento de orto-metalizacion para la sintesis de 1-(tetrazol-5-il)bencenos sustituidos en la posicion 2.
FI962261A (fi) N-bis- tai N-tris-((1,2-dikarboksyyli-etoksi)-etyyli)amiinijohdannaiset, niiden valmistus ja käyttö
WO2003024400A3 (en) Process for the preparation of 1,5-diarylpyrazoles
PT97479A (pt) Processo de preparacao de {i}benzotieno{2,3(1h,4h)-dionas e de composicoes farmaceuticas que as contem
PT1282617E (pt) Derivados de hidantoína com afinidade para os receptores da somatostatina
WO2000012480A3 (de) Substituierte 3-aryl-pyrazole
NZ330464A (en) Methods for the preparation of biphenyl isoxazole sulfonamides
MX9603199A (es) Antagonistas de receptores a endotelina.
GB9323162D0 (en) 4-(1h-2-methylimidazo(4,5-c)pyridinylmethyl)phenylsulphonamid e derivatives as antagonists of paf
BR9503845A (pt) Processo para a preparação de um composto e composto obtido
BG102287A (bg) 1-ар(алк)ил-имидазолин-2-они с дизаместен аминов остатък на 4-място, с антиконвулсивно действие и метод за получаването им
ATE282608T1 (de) Chinoxalindionen
DE50001717D1 (en) Herbizide substituierte thienocycloalk(en)ylamino-1,3,5-triazine
BG101236A (bg) Хербициден състав
ES552024A0 (es) Un metodo para preparar derivados de 1-amino-2-benzoilpirrol
EP0700395A1 (en) INDOLA DERIVATIVES AS INHIBITORS OF STEROIDAL 5-g (a) -REDUCTASE
MX9806195A (es) Procedimiento para la obtencion de cianofeniluracilos substituidos a partir de cianofenilamidas de acidos aminoalquenoicos substituidos.